CLINICAL STUDIES ON SBT/CPZ COMBINATION (1:1)
1984 Volume 32 Issue Supplement4 Pages 266-271
Details
1984 Volume 32 Issue Supplement4 Pages 266-271
The clinical efficacy of the combination of a new β-lactarnase inhibitor, sulbactam (SBT), with CPZ (1:1) was evaluated in 15 patients aged 37-83 years with respiratory tract infection (6 cases) and with urinary tract infection (9 cases). A daily does of this drug was 2-4 g by intravenous injection twice a day and duration of SBT/CPZ combination (1:1) therapy was for 4 to 14 days.
The results were as follows.
1. Clinical response to SBT/CPZ combination (1:1) therapy of respiratory tract infection was good in 2 cases, fair in 2 cases, poor in 2 cases and that of urinary tract infection was excellent in 4 cases and good in 5 cases. Efficacy rate was 73.3%.
2. As a side effect, eosinophilia (3267/mm3) was transiently shown in one case and elevation of GOT & GPT was shown in other one case.
However, it was reversible, and no other side effects were observed.
